Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Apr;40(4):531-5.
doi: 10.1136/gut.40.4.531.

Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis

Affiliations

Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis

H Yamaguchi et al. Gut. 1997 Apr.

Abstract

Background: Patients with severe acute pancreatitis die of complications closely related to the systemic activation of protease cascades.

Aim: To examine the effects of human C1 esterase inhibitor (C1 INH) and antithrombin III (AT III) on two experimental models of acute pancreatitis.

Methods: Oedematous pancreatitis was induced by continuous intravenous infusion of caerulein and haemorrhagic pancreatitis by retrograde injection of sodium taurocholate into the biliopancreatic duct. C1 INH and AT III were given intravenously, either before or after the induction of pancreatitis. Treatment with C1 INH and AT III had no beneficial effect on oedematous pancreatitis. On the other hand, combined C1 INH and AT III therapy improved the survival in haemorrhagic pancreatitis compared with treatment with human serum albumin. This reduction in mortality was found regardless of whether the treatment was given prophylactically or therapeutically.

Conclusions: Treatment with C1 INH and AT III represents a promising therapeutic concept for patients with severe haemorrhagic pancreatitis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. FEBS Lett. 1979 Jan 1;97(1):111-5 - PubMed
    1. Gut. 1995 Sep;37(3):434-40 - PubMed
    1. J Clin Invest. 1982 Feb;69(2):462-8 - PubMed
    1. J Clin Invest. 1983 Jan;71(1):149-58 - PubMed
    1. Gen Pharmacol. 1983;14(2):209-29 - PubMed

Publication types

MeSH terms